Inhibition studies on ASPRV1 may help to understand its contribution to skin barrier dysfunction [1,51], the herein described sensitivity of the enzyme to protease inhibitors reinforces the interest in studying how ASPRV1 could be potentially targeted in the treatment of immune disorders, including MS. Here, ASPRV1 is linked to myeloid sarcoma.